The holy grail: pan-cancer-targeting T cells
Crowther and Dolton et al. identified an unconventional human T cell clone capable of killing many different types of cancer in vitro in an HLA-independent fashion while sparing healthy cells. Using genome-wide CRISPR-Cas9 screening, the researchers showed that the T cell clone recognized the ubiquitously expressed, mostly monomorphic, MHC-I-related protein MR1 on the surface of cancer cells when MR1 was loaded with a yet unidentified cancer-specific or cancer-associated ligand. Adoptive transfer of this T cell clone into immunodeficient NSG mice with leukemia reduced tumor burden and increased survival.
Grail's $1 Billion Bet on the Perfect Cancer Test
Pan-cancer T cell atlas links a cellular stress response state to
Discovery of a Pan-Cancer Killing T Cell
Targeting cancer with mRNA–lipid nanoparticles: key considerations
IJMS, Free Full-Text
The role of ROS in tumor infiltrating immune cells and cancer
PKU researchers depicts pan-cancer single-cel
IJMS, Free Full-Text
Getting to the heart of complex cancer mutations
Is Immunotherapy the Holy Grail for Pancreatic Cancer? - Pereira Lab
Cancer detection predicts tumors before they form: discovery
